AIDS-associated Kaposi sarcoma responds markedly to highly active antiretroviral therapy (HAART), probably because the CD4+ count improves and the HIV viral load decreases; however, there is some evidence that protease inhibitors in this regimen may block angiogenesis (although this has not been shown to have beneficial clinical effects in humans).